Table 1.
Prevalence of abnormalities detected in NSCLC subsets and in COPD
| Adenocarcinoma | SCC | COPD | |
|---|---|---|---|
| EGF receptor mutations | 5–15% frequency | Infrequent | EGF receptor amplification occurs |
| ELM4/ALK translocations | 5–15% frequency | Infrequent | Not detected |
| KRAS mutations | >15% frequency | Infrequent | Not detected |
| FGFR family amplification/overexpression | Infrequent | 20% frequency in FGFR1 amplification | Overexpression of FGF1/2 and FGFR1 detected |
| PI3KCA amplification | Infrequent | >30% frequency | Increased PI3K pathway activation |
| Loss of PTEN status | Infrequent | Mutations and methylation detected (10–40% frequency) | PTEN pathway down‐regulated |